Trials / Completed
CompletedNCT03482882
Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression
An Open-label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults With Parkinson's Disease and Depression
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- ACADIA Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy of pimavanserin for the treatment of depression in adults with Parkinson's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pimavanserin | Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets) |
Timeline
- Start date
- 2018-03-09
- Primary completion
- 2019-07-09
- Completion
- 2019-07-24
- First posted
- 2018-03-29
- Last updated
- 2020-08-31
- Results posted
- 2020-08-31
Locations
21 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03482882. Inclusion in this directory is not an endorsement.